Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | IMGN632: a novel CD123 ADC for R/R AML and BPDCN

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the phase I study (NCT03386513) investigating the novel CD123-targeting antibody-drug conjugate IMGN632, which holds promise for treating R/R acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and other CD123-positive malignancies. Dr Daver highlights how this agent will be moving forwards, and discusses the combinations that are planned. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.